MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562446 | Name: SB-7720770 2HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB-7720770 2HCl is a Rho kinase inhibitor.

Chemical Structure

SB-7720770 2HCl
SB-7720770 2HCl
CAS#607373-46-6

Theoretical Analysis

MedKoo Cat#: 562446

Name: SB-7720770 2HCl

CAS#: 607373-46-6

Chemical Formula: C15H20Cl2N8O2

Exact Mass: 0.0000

Molecular Weight: 415.28

Elemental Analysis: C, 43.38; H, 4.85; Cl, 17.07; N, 26.98; O, 7.71

Price and Availability

Size Price Availability Quantity
5mg USD 400.00 2 Weeks
10mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SB-7720770 2HCl; SB 7720770 2HCl; SB7720770 2HCl; SB-7720770 dihydrochloride; SB 7720770 dihydrochloride; SB7720770 dihydrochloride;
IUPAC/Chemical Name
4-(7-{[(3S)-3-Amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine dihydrochloride
InChi Key
HSROPTGRSYJPJY-JZGIKJSDSA-N
InChi Code
InChI=1S/C15H18N8O2.2ClH/c1-2-23-12-9(15(24)22-4-3-8(16)7-22)5-18-6-10(12)19-14(23)11-13(17)21-25-20-11;;/h5-6,8H,2-4,7,16H2,1H3,(H2,17,21);2*1H/t8-;;/m0../s1
SMILES Code
NC1=NON=C1C(N2CC)=NC3=C2C(C(N4C[C@@H](N)CC4)=O)=CN=C3.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SB-772077B 2HCl is a ROCK inhibitor with IC50s of 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively.
In vitro activity:
To be determined
In vivo activity:
SB-772077-B holds promise as a potential therapeutic option in cardiovascular, and other chronic, diseases. SB-772077-B induced vasorelaxation in rat aorta and showed impressive blood pressure reduction in hypertensive rats when administered orally. SB-772077-B was influential in lowering blood pressure in both spontaneously hypertensive and DOCA salt-induced hypertensive rats. Reference: J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. https://pubmed.ncbi.nlm.nih.gov/17018693/
Solvent mg/mL mM
Solubility
DMSO 38.3 92.30
Water 100.0 240.80
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 415.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. PMID: 17018693.
In vitro protocol:
To be determined
In vivo protocol:
1. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. PMID: 17018693.
1: Battershill JM, Fielder RJ. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice. Hum Exp Toxicol. 1998 Apr;17(4):193-205. Review. PubMed PMID: 9617631. 2: Vesselinovitch SD, Rao KV, Mihailovich N. Neoplastic response of mouse tissues during perinatal age periods and its significance in chemical carcinogenesis. Natl Cancer Inst Monogr. 1979 May;(51):239-50. Review. PubMed PMID: 384263. 3: Ledochowski A. Ledakrin--anticancerous medicine 1-nitro-9(3-dimethylaminopropylamino)-acridine -2HCl-H2O. Mater Med Pol. 1976 Jul-Sep;8(3):237-51. Review. PubMed PMID: 796591.